CO7010784A2 - Moléculas que son anticuerpos con especificidad por ox40 humano - Google Patents

Moléculas que son anticuerpos con especificidad por ox40 humano

Info

Publication number: CO7010784A2
Authority: CO; Colombia
Prior art keywords: specificity; antibodies; molecules; human
Prior art date: 2011-11-11

Application number

CO14099147A

Other languages

English (en)

Inventor

Ralph Adams

Pallavi Bhatta

Sam Phillip Heywood

David Paul Humphreys

Original Assignee

Ucb Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-11

Filing date

2014-05-08

Publication date

2014-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47388492&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7010784(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-08 Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa

2014-07-31 Publication of CO7010784A2 publication Critical patent/CO7010784A2/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Transplantation (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CO14099147A 2011-11-11 2014-05-08 Moléculas que son anticuerpos con especificidad por ox40 humano CO7010784A2 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161558545P	2011-11-11	2011-11-11

Publications (1)

Publication Number	Publication Date
CO7010784A2 true CO7010784A2 (es)	2014-07-31

Family

ID=47388492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CO14099147A CO7010784A2 (es)	2011-11-11	2014-05-08	Moléculas que son anticuerpos con especificidad por ox40 humano

Country Status (34)

Country	Link
US (2)	US9040048B2 (es)
EP (1)	EP2776469B1 (es)
JP (1)	JP6367714B2 (es)
KR (1)	KR102071054B1 (es)
CN (1)	CN103946240B (es)
AP (1)	AP2014007668A0 (es)
AR (1)	AR088820A1 (es)
AU (1)	AU2012333997B2 (es)
BR (1)	BR112014011404A2 (es)
CA (1)	CA2855174C (es)
CL (1)	CL2014001193A1 (es)
CO (1)	CO7010784A2 (es)
CY (1)	CY1122073T1 (es)
DK (1)	DK2776469T3 (es)
EA (1)	EA035112B1 (es)
EC (1)	ECSP14000329A (es)
ES (1)	ES2737998T3 (es)
HR (1)	HRP20191219T1 (es)
HU (1)	HUE044333T2 (es)
IL (1)	IL232420B (es)
LT (1)	LT2776469T (es)
MA (1)	MA35724B1 (es)
MX (1)	MX358391B (es)
MY (1)	MY183795A (es)
PE (1)	PE20141995A1 (es)
PL (1)	PL2776469T3 (es)
PT (1)	PT2776469T (es)
SG (1)	SG11201402093RA (es)
SI (1)	SI2776469T1 (es)
TN (1)	TN2014000206A1 (es)
TR (1)	TR201910721T4 (es)
TW (1)	TWI588155B (es)
UA (1)	UA112203C2 (es)
WO (1)	WO2013068563A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2398498T3 (pl) *	2009-02-17	2019-03-29	Ucb Biopharma Sprl	Cząsteczki przeciwciał swoiste wobec ludzkiego OX40
WO2011030107A1 (en) *	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
CN103221427B (zh)	2010-08-23	2016-08-24	德克萨斯州立大学董事会	抗ox40抗体和使用其的方法
MX2014002769A (es) *	2011-09-16	2014-06-11	Ucb Pharma Sa	Anticuerpos neutralizantes para las exotoxinas principales tcda y tcdb de clostridium difficile.
GB201116092D0 (en)	2011-09-16	2011-11-02	Bioceros B V	Antibodies and uses thereof
GB201223276D0 (en)	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
NZ712903A (en)	2013-03-18	2018-07-27	Biocerox Prod Bv	Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2015041515A1 (en)	2013-09-19	2015-03-26	N.V. Nutricia	Improved process for the humanization of animal skim milk
MX2016012779A (es)	2014-03-31	2017-04-27	Genentech Inc	Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
BR112017015880A2 (pt)	2015-03-03	2018-07-31	Kymab Ltd	anticorpos, usos e métodos
EP3268037B1 (en)	2015-03-09	2022-08-31	Celldex Therapeutics, Inc.	Cd27 agonists
GB201506868D0 (en) *	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method for protein purification
GB201506869D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
EP3292152A1 (en)	2015-05-07	2018-03-14	Agenus Inc.	Anti-ox40 antibodies and methods of use thereof
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
MA43017A (fr) *	2015-10-02	2018-08-08	Hoffmann La Roche	Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
EP3363816A4 (en) *	2015-10-15	2019-10-09	Dingfu Biotarget Co., Ltd.	ANTI-OX40 ANTIBODIES AND USES THEREOF
JP7089470B2 (ja)	2015-12-02	2022-06-22	アジェナスインコーポレイテッド	抗体およびその使用方法
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
AU2016364891A1 (en) *	2015-12-03	2018-06-07	Agenus Inc.	Anti-OX40 antibodies and methods of use thereof
CN109475603B (zh)	2016-06-20	2023-06-13	科马布有限公司	抗pd-l1抗体
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3538152A4 (en) *	2016-11-09	2020-09-30	Agenus Inc.	ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
KR20210035805A (ko)	2018-06-15	2021-04-01	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
JP2022543187A (ja)	2019-08-02	2022-10-11	ユーシービーバイオファルマエスアールエル	抗体を精製するための方法
JP2023509359A (ja)	2019-12-17	2023-03-08	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	鉄依存性細胞分解の誘導物質との併用抗癌療法
JP2023507115A (ja)	2019-12-17	2023-02-21	アムジエン・インコーポレーテツド	治療における使用のためのデュアルインターロイキン－２／ｔｎｆ受容体アゴニスト
CN116096906A (zh)	2020-06-29	2023-05-09	旗舰创业创新五公司	工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR20230165276A (ko)	2021-03-31	2023-12-05	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
EP4363059A1 (en)	2021-06-29	2024-05-08	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
US5821332A (en)	1993-11-03	1998-10-13	The Board Of Trustees Of The Leland Stanford Junior University	Receptor on the surface of activated CD4+ T-cells: ACT-4
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0124317D0 (en)	2001-10-10	2001-11-28	Celltech R&D Ltd	Biological products
US20040146948A1 (en)	2002-10-18	2004-07-29	Centenary Institute Of Cancer Medicine And Cell Biology	Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
ITRM20030601A1 (it)	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
ITRM20050290A1 (it)	2005-06-07	2006-12-08	Lay Line Genomics Spa	Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
TWI461436B (zh)	2005-11-25	2014-11-21	Kyowa Hakko Kirin Co Ltd	人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AU2006322445B2 (en)	2005-12-05	2011-05-12	Symphogen A/S	Anti-orthopoxvirus recombinant polyclonal antibody
US20070224627A1 (en)	2006-03-23	2007-09-27	Lawrence Horowitz	Facilitation of translocation of molecules through the gastrointestinal tract
CN101668776A (zh)	2007-02-27	2010-03-10	健泰科生物技术公司	拮抗剂ox40抗体及其在炎性和自身免疫疾病的治疗中的用途
CN101842387B (zh)	2007-09-26	2014-05-07	Ucb医药有限公司	双特异性抗体融合物
CN105601745B (zh) *	2008-09-26	2020-09-08	Ucb医药有限公司	生物产品
PL2398498T3 (pl)	2009-02-17	2019-03-29	Ucb Biopharma Sprl	Cząsteczki przeciwciał swoiste wobec ludzkiego OX40
WO2011030107A1 (en)	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
JP5522668B2 (ja)	2010-02-03	2014-06-18	株式会社ブリヂストン	タイヤ構成部材の切断装置及び製造方法
DK2776466T3 (da) *	2011-11-11	2017-11-20	Ucb Biopharma Sprl	Albuminbindende antistoffer og bindingsfragmenter deraf

2012
- 2012-09-11 UA UAA201404941A patent/UA112203C2/uk unknown
- 2012-11-08 US US13/672,077 patent/US9040048B2/en not_active Expired - Fee Related
- 2012-11-09 BR BR112014011404A patent/BR112014011404A2/pt not_active Application Discontinuation
- 2012-11-09 MX MX2014005564A patent/MX358391B/es active IP Right Grant
- 2012-11-09 AU AU2012333997A patent/AU2012333997B2/en not_active Ceased
- 2012-11-09 AR ARP120104230A patent/AR088820A1/es unknown
- 2012-11-09 CN CN201280055398.8A patent/CN103946240B/zh not_active Expired - Fee Related
- 2012-11-09 EA EA201400565A patent/EA035112B1/ru not_active IP Right Cessation
- 2012-11-09 PT PT12803508T patent/PT2776469T/pt unknown
- 2012-11-09 LT LTEP12803508.6T patent/LT2776469T/lt unknown
- 2012-11-09 JP JP2014540489A patent/JP6367714B2/ja not_active Expired - Fee Related
- 2012-11-09 TW TW101141760A patent/TWI588155B/zh not_active IP Right Cessation
- 2012-11-09 WO PCT/EP2012/072325 patent/WO2013068563A2/en active Application Filing
- 2012-11-09 CA CA2855174A patent/CA2855174C/en active Active
- 2012-11-09 ES ES12803508T patent/ES2737998T3/es active Active
- 2012-11-09 MY MYPI2014701189A patent/MY183795A/en unknown
- 2012-11-09 TR TR2019/10721T patent/TR201910721T4/tr unknown
- 2012-11-09 AP AP2014007668A patent/AP2014007668A0/xx unknown
- 2012-11-09 HU HUE12803508 patent/HUE044333T2/hu unknown
- 2012-11-09 KR KR1020147015520A patent/KR102071054B1/ko active IP Right Grant
- 2012-11-09 SI SI201231633T patent/SI2776469T1/sl unknown
- 2012-11-09 PE PE2014000673A patent/PE20141995A1/es active IP Right Grant
- 2012-11-09 DK DK12803508.6T patent/DK2776469T3/da active
- 2012-11-09 PL PL12803508T patent/PL2776469T3/pl unknown
- 2012-11-09 SG SG11201402093RA patent/SG11201402093RA/en unknown
- 2012-11-09 EP EP12803508.6A patent/EP2776469B1/en active Active
2014
- 2014-05-01 IL IL232420A patent/IL232420B/en active IP Right Grant
- 2014-05-07 CL CL2014001193A patent/CL2014001193A1/es unknown
- 2014-05-08 EC ECIEPI2014329A patent/ECSP14000329A/es unknown
- 2014-05-08 CO CO14099147A patent/CO7010784A2/es unknown
- 2014-05-08 TN TNP2014000206A patent/TN2014000206A1/en unknown
- 2014-06-05 MA MA37104A patent/MA35724B1/fr unknown
2015
- 2015-04-27 US US14/697,142 patent/US9873735B2/en active Active
2019
- 2019-07-05 HR HRP20191219TT patent/HRP20191219T1/hr unknown
- 2019-07-23 CY CY20191100781T patent/CY1122073T1/el unknown

Also Published As

Publication number	Publication date
AU2012333997A1 (en)	2014-05-29
EA035112B1 (ru)	2020-04-28
PT2776469T (pt)	2019-07-25
TR201910721T4 (tr)	2019-08-21
CA2855174C (en)	2021-11-02
JP6367714B2 (ja)	2018-08-01
PE20141995A1 (es)	2014-12-06
WO2013068563A3 (en)	2013-06-27
HUE044333T2 (hu)	2019-10-28
MX358391B (es)	2018-08-17
SI2776469T1 (sl)	2019-09-30
MY183795A (en)	2021-03-16
NZ624583A (en)	2015-05-29
TW201326205A (zh)	2013-07-01
PL2776469T3 (pl)	2019-10-31
LT2776469T (lt)	2019-08-12
CY1122073T1 (el)	2020-11-25
CN103946240A (zh)	2014-07-23
AP2014007668A0 (en)	2014-05-31
WO2013068563A2 (en)	2013-05-16
JP2015506910A (ja)	2015-03-05
IL232420A0 (en)	2014-06-30
US9040048B2 (en)	2015-05-26
ES2737998T3 (es)	2020-01-17
MA35724B1 (fr)	2014-12-01
US20160031974A1 (en)	2016-02-04
AU2012333997B2 (en)	2017-08-31
ECSP14000329A (es)	2016-01-29
KR20140097329A (ko)	2014-08-06
WO2013068563A9 (en)	2014-06-19
MX2014005564A (es)	2014-11-10
UA112203C2 (uk)	2016-08-10
TN2014000206A1 (en)	2015-09-30
BR112014011404A2 (pt)	2017-05-30
CN103946240B (zh)	2018-02-23
IL232420B (en)	2019-02-28
TWI588155B (zh)	2017-06-21
CL2014001193A1 (es)	2014-12-26
SG11201402093RA (en)	2014-06-27
EP2776469A2 (en)	2014-09-17
CA2855174A1 (en)	2013-05-16
US9873735B2 (en)	2018-01-23
HRP20191219T1 (hr)	2019-10-04
US20130243772A1 (en)	2013-09-19
DK2776469T3 (da)	2019-07-29
EP2776469B1 (en)	2019-04-24
KR102071054B1 (ko)	2020-01-29
AR088820A1 (es)	2014-07-10
EA201400565A1 (ru)	2014-12-30

Publication	Publication Date	Title
CO7010784A2 (es)	2014-07-31	Moléculas que son anticuerpos con especificidad por ox40 humano
CO7071096A2 (es)	2014-09-30	Anticuerpos anti-lgr5 e inmunoconjugados
BR112014012137A2 (pt)	2017-05-30	anticorpos anti-fgfr2 e suas utilizações
DK3156416T3 (da)	2020-02-24	Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
CO7020871A2 (es)	2014-08-11	Anticuerpos anti-il-36r
BR112015002193A2 (pt)	2017-07-04	anticorpos anti-etbr e imunoconjugados
DK2934584T3 (da)	2020-05-18	Anti-gdf15-antistoffer
CO6811812A2 (es)	2013-12-16	Anticuerpo anti-b7-h3
DK2850101T3 (da)	2019-07-15	Anti-FcRn-antistoffer
DK3275892T3 (da)	2020-04-06	Præfusions-rsv-f-antigener
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
BR112012030311A2 (pt)	2017-01-24	anticorpo
DK3556774T3 (da)	2024-03-25	Anti-CD40-antistoffer og anvendelser deraf
DK3381943T3 (da)	2022-05-16	Anti-kit-antistoffer og anvendelser deraf
CR20140127A (es)	2014-08-20	Anticuerpo anti-abtcr
CO6890075A2 (es)	2014-03-10	Alcoholimetro calibrable
CR20130228A (es)	2013-09-18	Anticuerpos neutralizadores anti-ccl20
BR112013002297A2 (pt)	2016-05-24	anticorpos humanizados seguros e funcionais
CL2015001049A1 (es)	2015-10-16	Terapia de combinación de anticuerpos anti-her3
BR112014025037A2 (pt)	2018-07-31	anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
DK2668210T3 (da)	2020-08-24	Anti-kit antistoffer og anvendelser deraf
CO6791565A2 (es)	2013-11-14	Anticuerpos anti-notch1
DK3202789T3 (da)	2020-05-18	Anti-vla-4-antistoffer
DK3453723T3 (da)	2021-09-13	Anti-ASIC1-antistoffer og anvendelser deraf
EP2861619A4 (en)	2016-01-27	HUMAN BISPECIFIC ANTIBODY MOLECULAR EGFRVII